New FDA-approved drug can slow vision loss for those with ... - CBS News
WEBMar 1, 2023 · The Food and Drug Administration recently approved the first drug to treat geographic atrophy, a form of macular degeneration, which affects a person's central vision. Syfovre will be available...
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE …
WEBOct 20, 2023 · SYFOVRE ® (pegcetacoplan injection) is the first and only approved therapy for geographic atrophy (GA). By targeting C3, SYFOVRE is designed to provide comprehensive control of the complement...
What to Know About Syfovre and Izervay for Geographic Atrophy
WEBFeb 18, 2024 · Two new drugs – Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) – were approved in 2023 for geographic atrophy, a potentially debilitating type of dry age-related macular degeneration (AMD). The disease affects about one million Americans and can lead to significant vision loss.
FDA Approves First Geographic Atrophy Treatment SYFOVRE
WEBFeb 18, 2023 · A groundbreaking, new frontier in macular degeneration treatment has been announced! With the FDA’s approval of Syfovre™, for the first time there’s hope to preserve sight for millions of patients with the advanced stage of dry macular degeneration (dry AMD), called geographic atrophy (GA).
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First …
WEBFeb 17, 2023 · SYFOVRE™ (pegcetacoplan injection) is the first and only approved therapy for geographic atrophy (GA). By targeting C3, SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system.
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate …
WEBNov 4, 2023 · SYFOVRE ® (pegcetacoplan injection) is the first and only approved therapy for geographic atrophy (GA). By targeting C3, SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system.
FDA Approves First and Only Treatment for Geographic Atrophy, …
WEBFeb 17, 2023 · BrightFocus Foundation celebrates the U.S. Food and Drug Administration’s approval of Syfovre (pegcetacoplan injection), the first-ever treatment to slow the progression of vision loss from geographic atrophy, an advanced form of dry age-related macular degeneration and a leading cause of blindness.
First drug to treat dry AMD approved for use in the US
WEBFeb 21, 2023 · The first ever drug to treat dry age-related macular degeneration (AMD) has been approved for use in the US. The Food and Drug Administration (FDA) has cleared the drug pegcetacoplan, known as Syfovre, for use in patients.
First and only FDA-approved drug to treat advanced macular ... - CBS News
WEBApr 18, 2023 · The new FDA-approved treatment, Syfovre, is a breakthrough to treat advanced macular degeneration.
FDA Approves Syfovre for Geographic Atrophy, a Potentially …
WEBFeb 22, 2023 · On February 17, the U.S. Food and Drug Administration (FDA) gave the go-ahead for pegcetacoplan, to be marketed as Syfovre, bringing new hope to people diagnosed with geographic atrophy (GA),...